Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in stomach and esophageal cancer
- Trial result
Stomach and esophageal cancer
Tislelizumab (anti–PD-1) + chemo extends OS to 17.2mo in 1L advanced ESCC with 3-year durability
Tislelizumab is an anti–PD-1 monoclonal antibody designed to limit Fcγ receptor binding on macrophages, here combined with investigator-selected platinum-based chemotherapy as first-line treatment for unresectable…
NCT03783442 - New trial
Stomach and esophageal cancer
Phase 2 toripalimab induction and post-chemoradiation treatment targets locally advanced esophageal squamous cancer
Vanderbilt-Ingram Cancer Center is running this Phase 2 window-of-opportunity study in treatment-naive, resectable stage II-IVA esophageal squamous cell carcinoma. Participants receive induction toripalimab, a…
NCT07836049 Exploratory - New trial Spotlight
Stomach and esophageal cancer
Phase 3 ASP2138 CLDN18.2×CD3 T-cell engager adds to first-line treatment for gastric and GEJ cancer
Astellas Pharma Global Development is running this randomized, double-blind Phase 3 study in locally advanced unresectable or metastatic HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction…
NCT07673887 Registrational - Trial result Spotlight
Stomach and esophageal cancer
Evorpacept (CD47 blocker) + TRP lifts ORR in 2L/3L HER2+ gastric/GEJ—PFS flat in ITT
Evorpacept blocks the CD47–SIRPα interaction to enhance macrophage-mediated tumor-cell killing, here combined with trastuzumab + ramucirumab + paclitaxel (TRP). In the randomized Phase II portion of ASPEN-06…
NCT05002127 - New trial
Stomach and esophageal cancer
Phase 1b/2 intratumoral 2141-V11 CD40 agonist added to ongoing first-line PD-1 therapy in gastroesophageal adenocarcinoma
Memorial Sloan Kettering Cancer Center is running this Phase 1b/2, open-label study testing intratumoral 2141-V11, a CD40 agonist antibody, added to ongoing anti–PD-1 therapy with or without 5-FU in advanced…
NCT07818018 Exploratory - Trial result
Stomach and esophageal cancer
Camrelizumab (PD-1) + nimotuzumab (EGFR mAb) delivers 32.6% ORR in 2L advanced ESCC
Camrelizumab is an anti–PD-1 immune checkpoint inhibitor combined with nimotuzumab, an anti-EGFR monoclonal antibody, tested in a Chinese multicenter single-arm Phase II second-line study in advanced esophageal…
NCT03766178 - Trial result
Stomach and esophageal cancer
Nivolumab (PD-1) + chemo or nivolumab + ipilimumab (CTLA-4) sustains OS benefit at 5 years in 1L advanced ESCC
Nivolumab, a PD-1 checkpoint inhibitor, combined with platinum/fluoropyrimidine chemotherapy—or paired with ipilimumab (CTLA-4)—was evaluated versus chemotherapy alone in the open-label Phase 3 CheckMate 648 trial…
NCT03143153 - Trial result Spotlight
Stomach and esophageal cancer
ONO-4578 (EP4/PGE2-axis antagonist) + nivolumab + oxaliplatin chemo improves PFS in 1L HER2-negative gastric/GEJ cancer
ONO-4578 is an oral, selective EP4 antagonist designed to blunt PGE2-driven tumor immunosuppression and potentially deepen anti–PD-1 activity when combined with nivolumab. In this multicenter, double-blind,…
- New trial Spotlight
Stomach and esophageal cancer
Phase 3 cadonilimab PD-1×CTLA-4 bispecific antibody + CAPOX vs CAPOX ± nivolumab in 1L HER2-negative gastric/GEJ
Akeso’s randomized, double-blind, multi-regional Phase 3 trial (NCT07700979) tests whether adding cadonilimab—a PD-1 (CD279) and CTLA-4 dual-targeting bispecific antibody—improves overall survival versus a control…
NCT07700979 Registrational - New trial
Stomach and esophageal cancer
Phase 1/2 ifinatamab deruxtecan (B7-H3 topo-I ADC) in 2L/3L ESCC
This Phase 1/2 open-label KEYMAKER-U06 umbrella platform substudy evaluates ifinatamab deruxtecan (I-DXd; DS-7300a) in participants with unresectable locally advanced or metastatic esophageal squamous cell carcinoma…
NCT07405151 Exploratory - Trial result
Stomach and esophageal cancer
Tislelizumab (PD-1) + CAPOX vs CAPOX/FOLFOX Chemo Backbone Shows No Clear PFS/ORR Win in 1L HER2− GC/GEJ (MAIC)
Tislelizumab is an anti–PD-1 monoclonal antibody combined here with fluoropyrimidine/platinum chemotherapy (CAPOX or FOLFOX) for first-line unresectable/metastatic HER2-negative gastric/gastroesophageal junction…
NCT03777657 - Trial result
Stomach and esophageal cancer
Zongertinib + T-DXd Shows Early Responses in Trastuzumab-Pretreated HER2+ mGEAC
Zongertinib is an oral, irreversible HER2-selective TKI designed to spare wild-type EGFR, here combined with trastuzumab deruxtecan (T-DXd), a HER2-directed topoisomerase I ADC, in Cohort C of the Phase Ib/II Beamion…
NCT06324357 - Trial result
Stomach and esophageal cancer
Avelumab (anti–PD-L1) + modified DCF perioperative chemo delivers 61% 5-year OS in locally advanced GEA
Avelumab, a PD-L1 checkpoint inhibitor, was combined with perioperative modified DCF (docetaxel/cisplatin/5-FU) in a single-arm Phase II study in locally advanced gastro-esophageal adenocarcinoma (cT3–4 and/or N+, PS…
NCT03288350 - Trial result
Stomach and esophageal cancer
Durvalumab (PD-L1) + CROSS boosts MPR to 54% in resectable esophageal adenocarcinoma; tremelimumab (CTLA-4) adds toxicity without benefit
Durvalumab is an anti–PD-L1 antibody, and tremelimumab is an anti–CTLA-4 antibody; in the Phase II RICE trial (NCT04159974), 56 patients with locally advanced, non-metastatic esophageal adenocarcinoma (≥uT3/Nx or…
NCT04159974 - Trial result Spotlight
Stomach and esophageal cancer
Zanidatamab (dual HER2 bispecific; ECD2/4) + chemo in 1L HER2+ mGEA shows early ERBB2 ctDNA clearance tied to 12.5-mo mPFS
Zanidatamab is a dual HER2-targeted bispecific antibody (binding HER2 extracellular domains 2 and 4) evaluated with platinum/fluoropyrimidine chemotherapy (mFOLFOX6, CAPOX, or 5-FU/cisplatin) in a Phase 2, 1L HER2+…
NCT03929666 - Trial result Spotlight
Stomach and esophageal cancer
Durvalumab (PD-L1 blockade) + perioperative FLOT boosts EFS across completion strata in resectable G/GEJ cancer (MATTERHORN)
Durvalumab (anti–PD-L1 monoclonal antibody) was added to perioperative FLOT (5-FU/leucovorin/oxaliplatin/docetaxel) in MATTERHORN, a global, double-blind Phase 3 trial in untreated, resectable…
NCT04592913 - Trial result
Stomach and esophageal cancer
Tislelizumab (PD-1) + chemo adds ~2.6 months Q‑TWiST in peritoneal mets gastric/GEJ cancer
Tislelizumab (TIS), an anti–PD-1 monoclonal antibody engineered to reduce FcγR binding, was evaluated with fluoropyrimidine/platinum chemotherapy versus placebo (PBO) + chemotherapy in the global Phase 3,…
NCT03777657 - Trial result
Stomach and esophageal cancer
SHR-A1904 (garetatug rezetecan) CLDN18.2 ADC posts 25.5% ORR in heavily pretreated CLDN18.2+ solid tumors
SHR-A1904 is an investigational claudin-18.2 (CLDN18.2)–targeting antibody–drug conjugate evaluated in a global Phase 1/2a dose-escalation/optimization study in CLDN18.2-expressing relapsed/refractory solid tumors…
NCT05277168 - Trial result
Stomach and esophageal cancer
Avatrombopag (TPO-R agonist) sharply improves platelet recovery and “on-time” chemo delivery in persistent CIT (ACT‑GI)
ACT‑GI (NCT05772546) randomized patients with gastrointestinal malignancies and persistent chemotherapy‑induced thrombocytopenia (Plt <85×10^9/L on day 1 of a planned cycle) to avatrombopag 40mg PO daily vs placebo…
NCT05772546 - Trial result
Stomach and esophageal cancer
Zanidatamab (dual-HER2 bispecific) + PD-1 tislelizumab delivers OS gains regardless of PD-L1 in 1L HER2+ mGEA
Zanidatamab is a HER2-targeted bispecific antibody that binds two HER2 epitopes; in HERIZON-GEA-01 (Phase 3; NCT05152147), it was combined with platinum/fluoropyrimidine chemotherapy (CAPOX or FP) plus the anti–PD-1…
NCT05152147 - Trial result
Stomach and esophageal cancer
ONO-4578 (EP4 antagonist) + nivolumab + oxaliplatin/fluoropyrimidine extends PFS in 1L HER2-negative G/GEJ
ONO-4578 is an oral prostaglandin E2 (PGE2)–EP4 receptor antagonist intended to reverse myeloid-driven immunosuppression and potentially deepen anti–PD-1 benefit when added to nivolumab + chemotherapy. In the…
NCT06256328 - Trial result
Stomach and esophageal cancer
Pembrolizumab + Trastuzumab (PD-1/HER2) Sustains OS Gain in HER2+ G/GEJ Cancer
Pembrolizumab is a PD-1 inhibitor added to trastuzumab, an anti-HER2 antibody, plus platinum/fluoropyrimidine chemotherapy in the randomized Phase 3 KEYNOTE-811 first-line trial for untreated advanced/metastatic…
NCT03615326 - New trial
Stomach and esophageal cancer
Phase 2 cadonilimab PD-1×CTLA-4 bispecific antibody plus FLOT in resectable gastric/GEJ cancer
This Memorial Sloan Kettering–sponsored Phase 2, single-arm perioperative study tests whether adding cadonilimab to FLOT can safely deepen pathologic responses in locally advanced, resectable, HER2-negative gastric…
NCT07631000 Exploratory - New trial
Stomach and esophageal cancer
Phase 2 Olanzapine dopamine D2/5-HT2A antagonist to prevent weight loss in gastric cancer
This single-center, randomized, open-label Phase 2 supportive-care study at the University of Illinois Cancer Center (University of Illinois Chicago) tests whether adding low-dose olanzapine (2.5 mg by mouth once…
NCT07581405 Exploratory - New trial
Stomach and esophageal cancer
Phase 2 tislelizumab PD-1 inhibitor plus platinum/fluoropyrimidine chemo in PD-L1+ gastroesophageal cancers.
This open-label, single-arm Phase 2 study sponsored by BeOne Medicines evaluates tislelizumab (a PD-1/CD279–blocking monoclonal antibody designed to restore anti-tumor T-cell activity) combined with standard…
NCT07554521 Exploratory - Trial result Spotlight
Stomach and esophageal cancer
Zolbetuximab (anti-CLDN18.2 mAb) + chemo extends PFS to 20.5 months in Japanese 1L gastric/GEJ cancer
Zolbetuximab is a monoclonal antibody targeting CLDN18.2 and is combined here with platinum/fluoropyrimidine chemotherapy as first-line therapy for CLDN18.2-positive (typically defined in SPOTLIGHT/GLOW as ≥75% tumor…
NCT03504397 - New trial
Stomach and esophageal cancer
Phase 2 rinatabart sesutecan (Rina‑S) FRα-targeted antibody–drug conjugate with exatecan (topoisomerase I inhibitor)
Genmab’s Phase 2, open-label, multicohort study evaluates Rina‑S monotherapy in advanced/metastatic, progressive, unresectable gastrointestinal cancers after prior standard therapies, enrolling up to ~160…
NCT07539311 Exploratory - Trial result
Stomach and esophageal cancer
T-DXd (HER2 ADC) + rilvegostomig (PD-1×TIGIT) + fluoropyrimidine delivers 70% ORR as 1L HER2+ gastroesophageal triplet
Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate (topoisomerase I payload) and rilvegostomig is an Fc-reduced PD-1×TIGIT bispecific antibody; DESTINY-Gastric03 Part 4 arm A (NCT04379596)…
NCT04379596 - New trial Spotlight
Stomach and esophageal cancer
Phase 2/3 PF-08634404 PD-1×VEGF bispecific antibody + chemo in 1L PD-L1+ HER2− GE cancers
Pfizer’s Phase 2/3, multicenter, interventional study tests PF-08634404—an investigational bispecific antibody that targets PD-1 (immune checkpoint) and VEGF (angiogenesis signaling)—given with standard first-line…
NCT07392892 Exploratory - New trial Spotlight
Stomach and esophageal cancer
Phase II p-HIPEC with cisplatin + paclitaxel during gastrectomy for high-risk gastric/GEJ
Mayo Clinic evaluates heated intraperitoneal cisplatin/paclitaxel delivered intra-op alongside D2 gastrectomy to cut peritoneal relapse. Even with peri-op FLOT, peritoneal spread is the Achilles’ heel; p-HIPEC aims…
NCT07139951 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.